Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

Market Cap	24.01B -36.4%
Revenue (ttm)	5.65B -10.3%
Net Income	757.19M -48.0%
EPS	0.38 -47.9%
Shares Out	1.98B
PE Ratio	31.93
Forward PE	32.93
Dividend	0.20 (1.65%)
Ex-Dividend Date	Sep 23, 2026

Volume	5,235,096
Open	12.12
Previous Close	12.12
Day's Range	12.00 - 12.18
52-Week Range	11.12 - 19.19
Beta	0.22
Analysts	Buy
Price Target	16.85 (+38.8%)
Earnings Date	Oct 30, 2026

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 5,205
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2025, SHA:600161's revenue was 6.17 billion, an increase of 2.26% compared to the previous year's 6.03 billion. Earnings were 1.09 billion, a decrease of -29.59%.

Analyst Summary

According to 5 analysts, the average rating for 600161 stock is "Buy." The 12-month stock price target is ¥16.85, which is an increase of 38.80% from the latest price.

Price Target

¥16.85

(38.80% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error